# A Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers

> **NCT03293654** · PHASE1 · COMPLETED · sponsor: **mAbxience Research S.L.** · enrollment: 114 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** MB02
- **DRUG:** US licenced Avastin®
- **DRUG:** EU approved Avastin®

## Key facts

- **NCT ID:** NCT03293654
- **Lead sponsor:** mAbxience Research S.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-07
- **Primary completion:** 2019-05-29
- **Final completion:** 2019-05-29
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2021-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03293654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03293654, "A Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03293654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*